Pharmacokinetics, efficacy and safety of the rituximab biosimilar CT-P10.

about

Rituximab in the management of acute lymphoblastic leukemia.Past, Present, and Future of Rituximab-The World's First Oncology Monoclonal Antibody Therapy.The biosimilars journey: current status and ongoing challenges

P2860

Q47196522-D470E681-411D-4633-B448-87A481CBCF07 Q55283747-33C0F0FF-6734-47A8-8B16-30BF77E75E12 Q57298628-BA4BB73B-D201-4E81-ADF7-E3FFC01C81DF

P2860

Pharmacokinetics, efficacy and safety of the rituximab biosimilar CT-P10.

Item

http://www.wikidata.org/entity/Q38647397

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh

2017年學術文章

@zh-hant

name

Pharmacokinetics, efficacy and safety of the rituximab biosimilar CT-P10.

@en

type

Item

label

Pharmacokinetics, efficacy and safety of the rituximab biosimilar CT-P10.

@en

prefLabel

Pharmacokinetics, efficacy and safety of the rituximab biosimilar CT-P10.

@en

P1476

Pharmacokinetics, efficacy and safety of the rituximab biosimilar CT-P10

@en

P2093

Bertrand Coiffier

http://www.w3.org/2001/XMLSchema#string

P2860

Novel CD20 monoclonal antibodies for lymphoma therapy

B cells in rheumatoid arthritis: from pathogenic players to disease biomarkers.

The Rituximab Biosimilar CT-P10 in Rheumatology and Cancer: A Budget Impact Analysis in 28 European Countries

Barriers to the Access and Use of Rituximab in Patients with Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia: A Physician Survey.

A multicentre randomised controlled trial to compare the pharmacokinetics, efficacy and safety of CT-P10 and innovator rituximab in patients with rheumatoid arthritis

Pathogenesis of human B cell lymphomas.

Barriers to the Use of Trastuzumab for HER2+ Breast Cancer and the Potential Impact of Biosimilars: A Physician Survey in the United States and Emerging Markets

Evolution of cost structures in rheumatoid arthritis over the past decade.

The economic pressures for biosimilar drug use in cancer medicine

A phase I pharmacokinetics trial comparing PF-05280586 (a potential biosimilar) and rituximab in patients with active rheumatoid arthritis

P304

923-933

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1080/17512433.2017.1359537

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Bertrand Coiffier

P577

2017-08-02T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28766389

http://www.w3.org/2001/XMLSchema#string

Pharmacokinetics, efficacy and safety of the rituximab biosimilar CT-P10.

about

P2860

P2860

Pharmacokinetics, efficacy and safety of the rituximab biosimilar CT-P10.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698